GOSS - Gossamer Bio falls after UBS downgrades

2023-07-27 11:49:43 ET

• Gossamer Bio ( NASDAQ: GOSS ) fell ~4% Thursday noon after UBS downgraded the biopharmaceutical company, having said the next few years are more about execution.
• The ratings agency lowered the recommendation on the company to Neutral from Buy, and downgraded the price target to $1.25 from $8. The stock is currently trading at $1.22.
• The Ph3 readout, likely in 2025, is key for the company's investors to get more confidence, a recent research report said.
• The sell-side analysts give the stock a Buy rating, with an average price target of $5.95.
• Seeking Alpha's Quant Rating system gives the stock a Strong Sell rating.

For further details see: